You are here

CORTICOTROPIN RELEASING FACTOR RECEPTOR FUNCTION IN CNS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43MH065720-01
Agency Tracking Number: MH065720
Amount: $170,479.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
NEUROCRINE BIOSCIENCES, INC. 10555 SCIENCE CENTER DR
SAN DIEGO, CA 92121
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROBERT PETROSKI
 (858) 658-7770
 RPETROSKI@NEUROCRINE.COM
Business Contact
 PAUL HAWRAN
Phone: (858) 658-7658
Email: PHARWAN@NEUROCRINE.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Corticotropin releasing factor (CRF)
receptors are involved in the stress response; CRF produces generalized arousal
and anxiety-like behaviors in rodents. Two related genes encode the CRF1 and
CRF2 receptor subtypes, which exhibit distinct expression patterns in the
brain. Paradoxically, the brain areas involved in stress-related autonomic
responses express low or undetectable levels of CRF receptors. In addition, the
role of CRF in brain regions that express the highest levels of CRF receptors
(e.g. cortex and cerebellum) remains unexplored. CRF1 and CRF2 are G-protein
coupled receptors but the functional consequences of receptor activation are
poorly understood. Electrophysiological experiments are needed to elucidate how
CRF affects neuronal function. A major obstacle to conducting these experiments
is identifying the neurons that express CRF receptors in brain slices.
We propose to non-destructively label neurons that express CRF receptors by the
targeted expression of fluorescent proteins in transgenic mice. We will
generate two transgenic mouse lines labeling neurons that express CRF1 and
CRF2, respectively in order to unequivocally identify them for
electrophysiological recording. These animals will be used to expand our
understanding of CRF receptor function as well as to develop secondary assays
for the development CRF receptor subtype selective antagonists as therapeutic
agents.
PROPOSED COMMERCIAL APPLICATION:
Small molecule antagonists to CRF receptors are proposed to be therapeutic for treating anxiety and depression. Yet the mechanism by which the CRF system affects brain function is unknown. This research will produce and important tool for studying the function of CRF receptors in situ. It will enable development of functional (electrophysiological) assay(s) for CRF receptors in a native system and lead to the development of optimal small molecule drugs that target the CRF system.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government